Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERARAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 11 participantsLow
Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placeboRAP · people with pulmonary hypertension due to lung disease1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 28 participantsLow
Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placeboRAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 341 participantsHigh